Stronger Neo-Minophagen C
Hepatitis C, Chronic
Merck Sharp & Dohme LLCPhase 3Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Hepatitis C, Chronic cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ribavirin Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. | Phase 4 | A |
Pegylated Interferon Alpha2A Hoffmann-La Roche | Phase 4 | A |
Pegylated Interferon Α-2B Merck Sharp & Dohme LLC | Phase 3 | BBB |
Ledipasvir National Hepatology & Tropical Medicine Research Institute | Phase 3 | BB |
ADAFOSBUVIR Janssen Pharmaceutical K.K. | Phase 2 | BB |
View all 28 →
Same molecule, other indications
Stronger Neo-Minophagen C is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →